New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in ...

The Multiple Sclerosis Treatment Optimization Program (MSTOP) was motivated by research showing that Black and Hispanic ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 7.85% ...

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

Neurology Live ® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2025 Giants of Multiple ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in on FDA approval.

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Shares of Immunic (NASDAQ:IMUX) lost ~22% in the premarket on Wednesday after the immunology-focused biotech posted data from ...